{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:14:41Z","timestamp":1783332881767,"version":"3.54.6"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess treatment patterns for systemic lupus erythematosus from 2012 to 2024 and evaluate corresponding changes in serological activity and relapse rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed medical records of 1705 patients with systemic lupus erythematosus treated at a single centre between 2012 and 2024. Temporal trends in therapeutic approaches, glucocorticoid (GC) use, and clinical outcomes were analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Use of GC monotherapy declined from 58.3% in 2012 to 22.4% in 2024. Combination therapies (GC and hydroxychloroquine, with or without immunosuppressants) increased from 1.0% in 2015 to 41.6% in 2024, while biologics use rose from 0.9% in 2018 to 12.5% in 2024. Quadruple therapy (GC, hydroxychloroquine, immunosuppressants, and biologics) also expanded from 0.4% in 2018 to 6.2% in 2024. The mean GC dose decreased from 7.7\u00a0mg\/day in 2012 to 4.6\u00a0mg\/day in 2024, and the median dose, stable at 5\u00a0mg\/day for many years, declined to 4.6\u00a0mg in 2023 and 4.2\u00a0mg in 2024. The proportion of patients with elevated serological activity steadily decreased. Flare rates peaked at 8.1% in 2016 but stabilised at ~4% after 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that improved disease control can increasingly be achieved in real-world practice while reducing long-term GC dependence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roag001","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:24:55Z","timestamp":1768911895000},"page":"566-573","source":"Crossref","is-referenced-by-count":0,"title":["Developments in clinical practice treating systemic lupus erythematosus\u2014A single-centre retrospective longitudinal study in Japan"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0370-2297","authenticated-orcid":false,"given":"Kentaro","family":"Minowa","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yanagimoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eitaro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-2844","authenticated-orcid":false,"given":"Ayako","family":"Makiyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-4765","authenticated-orcid":false,"given":"Makio","family":"Kusaoi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3058-5778","authenticated-orcid":false,"given":"Masakazu","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University Nerima Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0565-1828","authenticated-orcid":false,"given":"Ken","family":"Yamaji","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-2954","authenticated-orcid":false,"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"2026070605222762900_ref1","doi-asserted-by":"publisher","first-page":"v19","DOI":"10.1093\/rheumatology\/keaa420","article-title":"Treatment targets in SLE: remission and low disease activity state","volume":"59","author":"Golder","year":"2020","journal-title":"Rheumatol (Oxf Engl)"},{"key":"2026070605222762900_ref2","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/rheumatology\/keaa403","article-title":"Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs","volume":"59","author":"Ruiz-Irastorza","year":"2020","journal-title":"Rheumatol (Oxf Engl)"},{"key":"2026070605222762900_ref3","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","article-title":"Definition and initial validation of a lupus low disease activity state (LLDAS)","volume":"75","author":"Franklyn","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026070605222762900_ref4","doi-asserted-by":"publisher","first-page":"e000538","DOI":"10.1136\/lupus-2021-000538","article-title":"2021 DORIS definition of remission in SLE: final recommendations from an international task force","volume":"8","author":"Vollenhoven","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026070605222762900_ref5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026070605222762900_ref6","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1007\/s12325-022-02148-8","article-title":"Treatment patterns and clinical characteristics of patients with systemic lupus erythematosus and musculoskeletal symptoms: a retrospective, observational study","volume":"39","author":"Bello","year":"2022","journal-title":"Adv Ther"},{"key":"2026070605222762900_ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13696998.2019.1678170","article-title":"Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States","volume":"23","author":"Kariburyo","year":"2020","journal-title":"J Med Econ"},{"key":"2026070605222762900_ref8","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/acr.24740","article-title":"Patterns of medication use in systemic lupus erythematosus: a multicenter cohort study","volume":"74","author":"Kandane-Rathnayake","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026070605222762900_ref9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1080\/14397595.2016.1192745","article-title":"Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: the JUDE study","volume":"27","author":"Minowa","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2026070605222762900_ref10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1080\/13696998.2020.1740236","article-title":"Treatment patterns and medical cost of systemic lupus erythematosus patients in Japan: a retrospective claims database study","volume":"23","author":"Miyazaki","year":"2020","journal-title":"J Med Econ"},{"key":"2026070605222762900_ref11","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/1756-185X.13363","article-title":"Disease severity and economic burden in Japanese patients with systemic lupus erythematosus: a retrospective, observational study","volume":"21","author":"Tanaka","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2026070605222762900_ref12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"2026070605222762900_ref13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/acr.23788","article-title":"Long-term impact of Belimumab on health-related quality of life and fatigue in patients with systemic lupus erythematosus: six years of treatment","volume":"71","author":"Strand","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026070605222762900_ref14","doi-asserted-by":"publisher","first-page":"17092","DOI":"10.1038\/s41598-017-17220-5","article-title":"Plasma metabolomic profile varies with glucocorticoid dose in patients with congenital adrenal hyperplasia","volume":"7","author":"Alwashih","year":"2017","journal-title":"Sci Rep"},{"key":"2026070605222762900_ref15","doi-asserted-by":"publisher","first-page":"e000310","DOI":"10.1136\/lupus-2018-000310","article-title":"Changing paradigms in the treatment of systemic lupus erythematosus","volume":"6","author":"Fanouriakis","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2026070605222762900_ref16","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/09612033211002269","article-title":"Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study","volume":"30","author":"Fasano","year":"2021","journal-title":"Lupus."},{"key":"2026070605222762900_ref17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/rheumatology\/keac225","article-title":"Low-dose glucocorticoids withdrawn in systemic lupus erythematosus: a desirable and attainable goal","volume":"62","author":"Ji","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026070605222762900_ref18","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/mr\/roaf020","article-title":"Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: a cross-sectional study based on the National Database of Health Insurance Claims","volume":"35","author":"Matsushita","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026070605222762900_ref19","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/mr\/roaf020","article-title":"Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: a cross-sectional study based on the National Database of Health Insurance Claims","volume":"35","author":"Sakurai","year":"2025","journal-title":"Mod Rheumatol"},{"key":"2026070605222762900_ref20","doi-asserted-by":"publisher","first-page":"e001336","DOI":"10.1136\/lupus-2024-001336","article-title":"Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort Study (SPOCS)","volume":"12","author":"Aringer","year":"2025","journal-title":"Lupus Sci Med"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag001\/66534044\/roag001.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/566\/66534044\/roag001.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/4\/566\/66534044\/roag001.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:23:10Z","timestamp":1783329790000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/4\/566\/8436880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag001","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,1,22]]}}}